While no immediate financial catalyst is present, the safety data may support broader physician adoption and payer reimbursement for CARDAMYST. Monitor upcoming commercial uptake metrics and potential international regulatory progress with the EMA.
Price Chart
Executive Summary
Milestone Pharmaceuticals (MIST) announced new data from its Phase 3 trials showing minimal blood pressure effects and low rates of hypotension or syncope with self-administered intranasal etripamil (CARDAMYST™), supporting its safety profile for at-home use in adults with PSVT. The data will be presented at ACC.26, reinforcing the drug's role as the first FDA-approved self-administered treatment for PSVT.
Key Facts
- CARDAMYST™ (etripamil) is FDA-approved for self-administration in adults with symptomatic PSVT, approved December 2025.
- Phase 3 data show minimal blood pressure change: mean systolic BP change of +1.8 mmHg (single dose) and 0.0 mmHg (repeat dose).
- Low incidence of treatment-emergent adverse events: hypotension (0.4%, 7/1,610) and syncope (0.2%, 4/1,610), all resolved without intervention.
- Two of the four syncope events occurred before drug administration.
- Data to be presented at ACC.26 via moderated poster and sponsored Expert Theater (non-CME).
Financial Impact
No direct financial figures disclosed; potential long-term commercial upside supported by safety data
Risk Factors
- Limited immediate commercial impact without sales figures or guidance.
- Forward-looking statements subject to regulatory, clinical, and market risks.
- Low market cap ($145M) increases volatility risk if adoption lags.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256248 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 7w ago | 8-K | $1.20 $0.7794 | ▼ −35.05% | ▼ −35.65% | $0.6878 (−42.68%) |
Aug 21, 2026 9w ago | Press Release | $1.06 $0.9178 | ▼ −13.00% | ▼ −12.48% | $0.6878 (−34.81%) |
Aug 12, 2026 10w ago | 8-K | $1.13 $1.05 | ▲ +6.67% | ▲ +4.77% | $0.6878 (+38.86%) |
May 26, 2026 22w ago | EFFECT | $1.40 $1.28 | ▲ +8.57% | ▲ +6.62% | $0.6878 (+50.87%) |
May 13, 2026 23w ago | S-3 | $1.63 $1.27 | ▲ +22.09% | ▲ +21.23% | $0.6878 (+57.80%) |
May 13, 2026 23w ago | 8-K | $1.72 $1.27 | ▼ −26.16% | ▼ −25.55% | $0.6878 (−60.01%) |
May 13, 2026 23w ago | Press Release | $1.72 $1.27 | ▼ −26.16% | ▼ −25.55% | $0.6878 (−60.01%) |
Mar 20, 2026 31w ago | Press Release | $1.36 $2.04 | ▲ +50.00% | ▲ +40.68% | $0.6878 (−49.43%) |
Mar 16, 2026 32w ago | Press Release | $1.69 $2.03 | ▲ +20.12% | ▲ +16.34% | $0.6878 (−59.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers